Skip to main content
Healthcare

STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues

STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues

Feed excerpt — reported by STAT News

Versant Ventures, Eli Lilly, and a handful of other investors will pour $100 million into a new startup devoted to solving a thorny gene therapy challenge.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.